// App-Quantinova.ai

PO‐114 : An investigational RNAi therapeutic (ALN‐CC5) targeting complement C5 for treatment of PNH and complement‐mediated diseases: exploratory analysis of interim phase 1/2 study results supports reduced eculizumab dosing in patients with PNH

Researchers

Presenter

  • A Hill

Principal Investigators

  • A Gaya

  • M Griffin

  • T Munir

  • A Borodovsky

  • N Kawahata

  • H McLean

  • K Shi

  • A Partisano

  • J Kim

  • N Najafian

  • A Urbano-Ispizua

Medical Centers

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Ra Pharmaceuticals Cambridge MA United States

Locations

  • United Kingdom

  • Spain

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • N/A

Biomarkers

  • Lactate dehydrogenase

Drug/Treatment

  • Cyclosporine A

  • Eculizumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved